These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 38728438)

  • 1. Empagliflozin inhibits increased Na influx in atrial cardiomyocytes of patients with HFpEF.
    Trum M; Riechel J; Schollmeier E; Lebek S; Hegner P; Reuthner K; Heers S; Keller K; Wester M; Klatt S; Hamdani N; Provaznik Z; Schmid C; Maier L; Arzt M; Wagner S
    Cardiovasc Res; 2024 Jul; 120(9):999-1010. PubMed ID: 38728438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Empagliflozin reduces Ca/calmodulin-dependent kinase II activity in isolated ventricular cardiomyocytes.
    Mustroph J; Wagemann O; Lücht CM; Trum M; Hammer KP; Sag CM; Lebek S; Tarnowski D; Reinders J; Perbellini F; Terracciano C; Schmid C; Schopka S; Hilker M; Zausig Y; Pabel S; Sossalla ST; Schweda F; Maier LS; Wagner S
    ESC Heart Fail; 2018 Aug; 5(4):642-648. PubMed ID: 30117720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase Gα oxidation.
    Kolijn D; Pabel S; Tian Y; Lódi M; Herwig M; Carrizzo A; Zhazykbayeva S; Kovács Á; Fülöp GÁ; Falcão-Pires I; Reusch PH; Linthout SV; Papp Z; van Heerebeek L; Vecchione C; Maier LS; Ciccarelli M; Tschöpe C; Mügge A; Bagi Z; Sossalla S; Hamdani N
    Cardiovasc Res; 2021 Jan; 117(2):495-507. PubMed ID: 32396609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual SGLT-1 and SGLT-2 inhibition improves left atrial dysfunction in HFpEF.
    Bode D; Semmler L; Wakula P; Hegemann N; Primessnig U; Beindorff N; Powell D; Dahmen R; Ruetten H; Oeing C; Alogna A; Messroghli D; Pieske BM; Heinzel FR; Hohendanner F
    Cardiovasc Diabetol; 2021 Jan; 20(1):7. PubMed ID: 33413413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitions of late INa and CaMKII act synergistically to prevent ATX-II-induced atrial fibrillation in isolated rat right atria.
    Liang F; Fan P; Jia J; Yang S; Jiang Z; Karpinski S; Kornyeyev D; Pagratis N; Belardinelli L; Yao L
    J Mol Cell Cardiol; 2016 May; 94():122-130. PubMed ID: 27066997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Off-target effects of sodium-glucose co-transporter 2 blockers: empagliflozin does not inhibit Na+/H+ exchanger-1 or lower [Na+]i in the heart.
    Chung YJ; Park KC; Tokar S; Eykyn TR; Fuller W; Pavlovic D; Swietach P; Shattock MJ
    Cardiovasc Res; 2021 Dec; 117(14):2794-2806. PubMed ID: 33135077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decoding empagliflozin's molecular mechanism of action in heart failure with preserved ejection fraction using artificial intelligence.
    Bayes-Genis A; Iborra-Egea O; Spitaleri G; Domingo M; Revuelta-López E; Codina P; Cediel G; Santiago-Vacas E; Cserkóová A; Pascual-Figal D; Núñez J; Lupón J
    Sci Rep; 2021 Jun; 11(1):12025. PubMed ID: 34103605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced CaMKII-Dependent Late I
    Lebek S; Pichler K; Reuthner K; Trum M; Tafelmeier M; Mustroph J; Camboni D; Rupprecht L; Schmid C; Maier LS; Arzt M; Wagner S
    Circ Res; 2020 Feb; 126(5):603-615. PubMed ID: 31902278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Empagliflozin directly improves diastolic function in human heart failure.
    Pabel S; Wagner S; Bollenberg H; Bengel P; Kovács Á; Schach C; Tirilomis P; Mustroph J; Renner A; Gummert J; Fischer T; Van Linthout S; Tschöpe C; Streckfuss-Bömeke K; Hasenfuss G; Maier LS; Hamdani N; Sossalla S
    Eur J Heart Fail; 2018 Dec; 20(12):1690-1700. PubMed ID: 30328645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dapagliflozin: A sodium-glucose cotransporter 2 inhibitor, attenuates angiotensin II-induced atrial fibrillation by regulating atrial electrical and structural remodeling.
    Zhan G; Wang X; Wang X; Li J; Tang Y; Bi H; Yang X; Xia Y
    Eur J Pharmacol; 2024 Sep; 978():176712. PubMed ID: 38906237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Empagliflozin protects against heart failure with preserved ejection fraction partly by inhibiting the senescence-associated STAT1-STING axis.
    Shi Y; Zhao L; Wang J; Liu X; Bai Y; Cong H; Li X
    Cardiovasc Diabetol; 2024 Jul; 23(1):269. PubMed ID: 39044275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Empagliflozin and liraglutide ameliorate HFpEF in mice via augmenting the Erbb4 signaling pathway.
    Ni XY; Feng XJ; Wang ZH; Zhang Y; Little PJ; Cao Y; Xu SW; Tang LQ; Weng JP
    Acta Pharmacol Sin; 2024 Aug; 45(8):1604-1617. PubMed ID: 38589689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The sodium-glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats.
    Lee HC; Shiou YL; Jhuo SJ; Chang CY; Liu PL; Jhuang WJ; Dai ZK; Chen WY; Chen YF; Lee AS
    Cardiovasc Diabetol; 2019 Apr; 18(1):45. PubMed ID: 30935417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiac Late Sodium Channel Current Is a Molecular Target for the Sodium/Glucose Cotransporter 2 Inhibitor Empagliflozin.
    Philippaert K; Kalyaanamoorthy S; Fatehi M; Long W; Soni S; Byrne NJ; Barr A; Singh J; Wong J; Palechuk T; Schneider C; Darwesh AM; Maayah ZH; Seubert JM; Barakat K; Dyck JRB; Light PE
    Circulation; 2021 Jun; 143(22):2188-2204. PubMed ID: 33832341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Load-independent effects of empagliflozin contribute to improved cardiac function in experimental heart failure with reduced ejection fraction.
    Connelly KA; Zhang Y; Desjardins JF; Nghiem L; Visram A; Batchu SN; Yerra VG; Kabir G; Thai K; Advani A; Gilbert RE
    Cardiovasc Diabetol; 2020 Feb; 19(1):13. PubMed ID: 32035482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct Cardiac Actions of the Sodium Glucose Co-Transporter 2 Inhibitor Empagliflozin Improve Myocardial Oxidative Phosphorylation and Attenuate Pressure-Overload Heart Failure.
    Li X; Lu Q; Qiu Y; do Carmo JM; Wang Z; da Silva AA; Mouton A; Omoto ACM; Hall ME; Li J; Hall JE
    J Am Heart Assoc; 2021 Mar; 10(6):e018298. PubMed ID: 33719499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ca
    Onal B; Gratz D; Hund TJ
    Am J Physiol Heart Circ Physiol; 2017 Dec; 313(6):H1227-H1239. PubMed ID: 28842436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na
    Uthman L; Baartscheer A; Bleijlevens B; Schumacher CA; Fiolet JWT; Koeman A; Jancev M; Hollmann MW; Weber NC; Coronel R; Zuurbier CJ
    Diabetologia; 2018 Mar; 61(3):722-726. PubMed ID: 29197997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nav1.5-dependent persistent Na+ influx activates CaMKII in rat ventricular myocytes and N1325S mice.
    Yao L; Fan P; Jiang Z; Viatchenko-Karpinski S; Wu Y; Kornyeyev D; Hirakawa R; Budas GR; Rajamani S; Shryock JC; Belardinelli L
    Am J Physiol Cell Physiol; 2011 Sep; 301(3):C577-86. PubMed ID: 21677263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Associations of Empagliflozin With Left Ventricular Volumes, Mass, and Function in Patients With Heart Failure and Reduced Ejection Fraction: A Substudy of the Empire HF Randomized Clinical Trial.
    Omar M; Jensen J; Ali M; Frederiksen PH; Kistorp C; Videbæk L; Poulsen MK; Tuxen CD; Möller S; Gustafsson F; Køber L; Schou M; Møller JE
    JAMA Cardiol; 2021 Jul; 6(7):836-840. PubMed ID: 33404637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.